Is Viking Therapeutics Incredibly Undervalued?
Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled the biotech's stock to a staggering 714% surge since the completion of the drug's Phase 1 trial on March 28, 2023.
Image Source: Getty Images.
Two key factors have fueled investor enthusiasm:
Source Fool.com
Viking Therapeutics Inc Stock
€62.14
0.840%
Currently there is a rather positive sentiment for Viking Therapeutics Inc with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 100 € shows a very positive potential of 60.93% compared to the current price of 62.14 € for Viking Therapeutics Inc.
